Interferon gamma immunoPET imaging to evaluate response to immune checkpoint inhibitors.
immune checkpoint inhibitors
immunoPET imaging
immunotherapy
interferon gamma
radioactive tracer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
08
2023
accepted:
08
11
2023
medline:
22
12
2023
pubmed:
22
12
2023
entrez:
22
12
2023
Statut:
epublish
Résumé
We previously developed a BALB/c mice bearing CT26 colorectal tumors were treated with combined ICI (anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death 1 (PD-1)). The [ We detected significantly higher intratumoral localization of [ These results support the use of IFNγ PET as a method to monitor immune activity
Identifiants
pubmed: 38130991
doi: 10.3389/fonc.2023.1285117
pmc: PMC10735274
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1285117Informations de copyright
Copyright © 2023 Hackett, Ramos, Barr, Bross, Viola and Gibson.
Déclaration de conflit d'intérêts
HG and NV are inventors on US 11,672,877-B2 “In vivo immunoimaging of interferon-gamma.” The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.